Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase III trial is to evaluate the efficacy of oral administration of
dehydroepiandrosterone (DHEA) combined with acolbifene (a selective estrogen receptor
modulator (SERM)) on vasomotor symptoms (hot flushes) in postmenopausal women.